8月10日，昭衍新药（06127.HK）盘中上涨5.24%，报28.92港元，成交额1.35亿港元。
消息面上，生命科学工具和服务板块延续强势，药明康德涨4.21%、药明生物涨4.88%、金斯瑞生物科技涨5.48%，板块全线走强。此前药明康德披露半年报，上半年营收288.97亿元同比增长38.93%，扣非净利润同比增长89.39%，并上调全年业绩指引，持续提振CXO板块情绪。叠加昭衍新药自身半年度业绩预告显示归母净利润预增884.9%至1377.4%，生物资产公允价值变动贡献净利润约7.03亿元至7.77亿元，业绩与板块共振推动股价延续反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.